Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue EClinicalMedicine Année : 2022

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis

Résumé

Background Summarized data of cardiovascular outcomes trials (CVOTs) of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have shown a reduction in major adverse cardiovascular event (MACE), whether these benefits are extended in certain risk groups (elderly or obese patients or those with a longer duration of diabetes) or certain minorities (Black participants) are not clearly established. We aimed to provide overall hazard ratios (HRs) estimates for MACE of SGLT2i and GLP-1 RAs stratified by age (< 65 years vs. ≥ 65 years and < 75 years vs. ≥ 75 years), sex (male vs. female), race (Black vs. White, Black vs. Asian, and White vs. Asian), body mass index (BMI: < 30 kg/m 2 vs. ≥ 30 kg/m 2), and duration of diabetes (< 10 years vs. ≥ 10 years).
Fichier principal
Vignette du fichier
1-s2.0-S2589537022004278-main.pdf (2.04 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03987854 , version 1 (14-02-2023)

Identifiants

Citer

Alhassane Diallo, Miguel Carlos-Bolumbu, Florence Galtier. Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. EClinicalMedicine, 2022, 54, ⟨10.1016/j.eclinm.2022.101697⟩. ⟨hal-03987854⟩
7 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More